Weimai Medical, founded in 2014, is a national high‑tech enterprise specializing in interventional imaging full‑process management and an integrated “eye‑hand‑brain” solution. Its product lines include high‑end flat‑panel DSA (Aurora), mobile and surgical C‑arms (mid C and small C), and interventional surgical robots, with technical synergies across lines. The company completed overseas M&A and has an international R&D, manufacturing and sales strategy; its Aurora DSA received NMPA and CE dual certification in 2020 and is used in multiple hospitals and exported to 20+ countries. In 2016 Weimai acquired the EC mid‑C brand, and its mid‑C product has CE and NMPA certifications and broad clinical adoption. The company’s self‑developed interventional surgical robot has completed animal experiments and is positioned to accelerate clinical progress and integration with DSA systems. The recent financing will be applied to brand promotion, domestic and overseas commercialization of certified C‑series products, and to speed clinical rollout of the surgical robot as part of its plan to complete an end‑to‑end interventional treatment management offering. Founded in 2014, Weimai Medical focuses on R&D and production of interventional diagnostic imaging equipment and related robotics. Its product lineup includes ground‑mounted intelligent flat‑panel DSA (极光), mobile and surgical C‑arms (large C, mid‑C, small C) and a remote‑operable interventional robot. 极光 DSA received CE certification in early 2020 and recently obtained NMPA approval; the company’s mid‑C product (acquired from Italy’s EC) also holds NMPA registration and has been sold internationally. Weimai reports installations of its DSA in multiple leading hospitals (including Beijing Tiantan Hospital, First Affiliated Hospital of Zhengzhou University, Zhengzhou Central Hospital and Hebei University Affiliated Hospital) and has overseas sales in 20+ countries for the acquired mid‑C product. The company positions its small‑C Elfinbot100 as a domestically high‑end alternative to imported orthopedics C‑arms. Management says the C+ proceeds will be used for brand building, product promotion and development of segmented models. Weimai highlights policy and market tailwinds for domestic large medical equipment and aims to accelerate domestic and international commercial expansion. Weimai Medical (founded 2014, Beijing) focuses on R&D, manufacturing and commercialization of interventional diagnostic and treatment equipment, with product lines that include large vascular DSA systems, mobile angiography (mid C), surgical C‑arms (small C) and interventional robots. The company reports more than 30 granted patents covering core technologies such as digital subtraction imaging and has pursued overseas M&A to build an international R&D, manufacturing and sales footprint. Weimai says its seven‑axis flat‑panel DSA delivers performance comparable to mid‑to‑high‑end international products while costing significantly less, aiming to enable domestic import substitution. Its devices are in trial or use at multiple top-tier Chinese hospitals and the company has completed clinical trials for its high‑end large C product with pending registration approval. Management plans to continue software and hardware upgrades across product lines and is investing heavily in interventional robot development and deeper integration of imaging and robotic solutions under 5G capabilities. The company recently completed a new financing round to support clinical promotion of certified products and to accelerate R&D of robotic systems.

Total raised

$61M

Funding rounds

3

Latest round

Series D

Latest activity

Apr 2021